PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0079731|b-cell lymphoma |
| Sentences | 2 |
| PubMedID- 22735172 | Generalized telangiectasia as the manifestation of intravascular large b-cell lymphoma complicated with breast cancer. |
| PubMedID- 22275822 | In a phase i clinical study, lipo-dox achieved the most prolonged circulation half-life (65 hours).73 however, tseng et al demonstrated that there were no differences in survival between free doxorubicin only (median survival time of 23 days) and lipo-dox (medium survival time of 23.5 days) in a murine b-cell lymphoma model.74 in patients with metastatic breast cancer, the median time to disease progression of 163 days represented the result of lipo-dox treatment and the median duration of response in responding patients (286 days) are comparable with those of doxil treatment.75 neutropenia, stomatitis, and skin toxicity were reported in many cases of lipo-dox administration. |
Page: 1